Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy
Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy
复制标题
DOI：
10.1080/02841860310016226
复制
发表时间：
2004-01-01
期刊：
影响因子：
3.1
通讯作者：
Shimizu, E
中科院分区：
文献类型：
--
作者：
Sako, T;Burioka, N;Shimizu, E
紫杉醇是一种治疗晚期非小细胞肺癌（NSCLC）的新药。每周一次的剂量可以增强抗肿瘤活性，同时使毒性最小化，但对免疫恢复知之甚少。10例NSCLC患者接受紫杉醇（80 mg/m2）给药，每周一次，共3周。监测自然杀伤（NK）活性、CD 3（-）CD 16（+）CD 56（+）NK细胞和分类计数。所有患者经紫杉醇治疗后均出现NK活性。NK活性显示在方案第8天降低27+/-9%（平均值+/-SE），在第15天降低37+/-7%（p < 0.05），在第29天恢复至基线的89+/-5%。每周紫杉醇治疗，NK细胞功能下降持续到第一个周期，但随后恢复。每周一次紫杉醇的免疫抑制作用可能低于顺铂等药物。
Paclitaxel is a new agent for advanced non-small cell lung cancer (NSCLC). Weekly doses may enhance antitumor activity while minimizing toxicity, but little is known about immune recovery. Paclitaxel (80 mg/m(2)) was administered to 10 patients with NSCLC, weekly during 3-week cycles. Natural killer (NK) activity, CD3(-)CD16(+)CD56(+) NK cells, and differential counts were monitored. NK activity appeared in all patients after treatment with paclitaxel therapy. NK activity showed a 27+/-9% decrease (mean+/-SE) on protocol day 8 and a 37+/-7% decrease on day 15 (p < 0.05) recovering to 89+/-5% of baseline on day 29. With weekly paclitaxel, a decrease in NK cell function persisted through the first cycle but then recovered. Weekly paclitaxel may be less immunosuppressive than agents such as cisplatin.